Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:ORMP

Oramed Pharmaceuticals - ORMP Stock Forecast, Price & News

$7.97
-0.44 (-5.23%)
(As of 11/28/2022 05:17 PM ET)
Add
Compare
Today's Range
$7.94
▼
$8.60
50-Day Range
$5.88
▼
$9.00
52-Week Range
$3.59
▼
$21.83
Volume
242,529 shs
Average Volume
785,839 shs
Market Capitalization
$311.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00

Oramed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
263.9% Upside
$29.00 Price Target
Short Interest
Bearish
7.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Oramed Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.91) to ($1.11) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

980th out of 1,040 stocks

Pharmaceutical Preparations Industry

475th out of 509 stocks

See Top Rated MarketRank™ Stocks Here
ORMP stock logo

About Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

November 26, 2022 | americanbankingnews.com
Zacks Small Cap Weighs in on Oramed Pharmaceuticals Inc.'s FY2022 Earnings (NASDAQ:ORMP)
November 21, 2022 | finance.yahoo.com
ORMP: Data from NASH Phase 2 Study – Positive Takeaways
November 20, 2022 | americanbankingnews.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Price Target Lowered to $35.00 at Alliance Global Partners
November 18, 2022 | finance.yahoo.com
Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study
November 17, 2022 | finance.yahoo.com
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH
November 16, 2022 | finance.yahoo.com
Oramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
November 14, 2022 | finance.yahoo.com
Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea
November 10, 2022 | finance.yahoo.com
Oramed Reports Third Quarter 2022 Financial Results
November 9, 2022 | finance.yahoo.com
Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH
October 17, 2022 | finance.yahoo.com
Oramed Pharmaceuticals (NASDAQ:ORMP) shareholders have earned a 27% CAGR over the last three years
October 14, 2022 | seekingalpha.com
ORMP Oramed Pharmaceuticals Inc.
October 7, 2022 | finance.yahoo.com
Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study
October 7, 2022 | marketwatch.com
Oramed Pharmaceuticals Sees Positive Oral Covid-19 Vaccine Data
October 7, 2022 | seekingalpha.com
Oramed oral COVID vaccine shows promise in phase 1 trial
October 7, 2022 | finance.yahoo.com
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
September 22, 2022 | seekingalpha.com
Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
September 13, 2022 | nasdaq.com
Oramed Gets Positive Mid-stage Results From NASH Trial With ORMD-0801
September 13, 2022 | markets.businessinsider.com
Oramed Oral Insulin Shows Evidence For NASH Treatment
September 13, 2022 | finance.yahoo.com
Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate
September 6, 2022 | finance.yahoo.com
Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 1, 2022 | finance.yahoo.com
Oramed Pharmaceuticals Inc. (ORMP)
August 25, 2022 | finance.yahoo.com
ORMP: Upcoming data from ORA-D-013-1 & NASH studies could be catalysts
August 1, 2022 | finance.yahoo.com
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
July 26, 2022 | markets.businessinsider.com
Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study
July 26, 2022 | finance.yahoo.com
Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial
See More Headlines
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Company Calendar

Last Earnings
1/10/2022
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
1/10/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORMP
CUSIP
N/A
CIK
1176309
Web
www.oramed.com
Phone
(844) 967-2633
Fax
972-2566-0004
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+263.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,240,000.00
Net Margins
-887.02%
Pretax Margin
-917.39%
Return on Equity
-22.41%
Return on Assets
-21.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
24.55
Quick Ratio
24.55

Sales & Book Value

Annual Sales
$2.70 million
Price / Sales
115.46
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.46 per share
Price / Book
1.79

Miscellaneous

Outstanding Shares
39,115,000
Free Float
36,416,000
Market Cap
$311.75 million
Optionable
Optionable
Beta
2.28

Key Executives

  • Mr. Nadav Kidron Esq.Mr. Nadav Kidron Esq. (Age 48)
    Pres, CEO & Exec. Chairman
    Comp: $1.23M
  • Mr. David Silberman CPA (Age 38)
    CFO & Treasurer
    Comp: $232.47k
  • Mr. Joshua Hexter (Age 52)
    Chief Operating & Bus. Officer
    Comp: $326.94k
  • Dr. Miriam Kidron Ph.D. (Age 82)
    Chief Scientific Officer & Director
    Comp: $420.06k
  • Mr. Michael Rabinowitz (Age 57)
    Chief Commercial Officer
    Comp: $360.18k
  • Mr. Netanel Derovan (Age 47)
    Chief Legal Officer & Company Sec.
  • Dr. Roy Eldor M.D.
    Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ORMP Stock - Frequently Asked Questions

Should I buy or sell Oramed Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ORMP shares.
View ORMP analyst ratings or view top-rated stocks.

What is Oramed Pharmaceuticals' stock price forecast for 2023?

2 Wall Street analysts have issued 1-year price targets for Oramed Pharmaceuticals' shares. Their ORMP share price forecasts range from $20.00 to $35.00. On average, they expect the company's stock price to reach $29.00 in the next year. This suggests a possible upside of 241.2% from the stock's current price.
View analysts price targets for ORMP or view top-rated stocks among Wall Street analysts.

How have ORMP shares performed in 2022?

Oramed Pharmaceuticals' stock was trading at $14.28 at the beginning of the year. Since then, ORMP stock has decreased by 40.5% and is now trading at $8.50.
View the best growth stocks for 2022 here.

When is Oramed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 10th 2023.
View our ORMP earnings forecast.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its quarterly earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.06. The biotechnology company earned $0.67 million during the quarter, compared to analyst estimates of $0.70 million. Oramed Pharmaceuticals had a negative trailing twelve-month return on equity of 22.41% and a negative net margin of 887.02%.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Jess S & Co. Inc. (0.94%), Two Sigma Advisers LP (0.85%), Two Sigma Investments LP (0.42%), Cubist Systematic Strategies LLC (0.30%), BlackRock Inc. (0.26%) and ETF Managers Group LLC (0.24%). Insiders that own company stock include Kevin Rakin and Nadav Kidron.
View institutional ownership trends.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $8.50.

How much money does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $332.48 million and generates $2.70 million in revenue each year. The biotechnology company earns $-22,240,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004.

This page (NASDAQ:ORMP) was last updated on 11/28/2022 by MarketBeat.com Staff